We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
-19.97%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$529M
AUM Growth
-$349M
Cap. Flow
-$100M
Cap. Flow %
-18.99%
Top 10 Hldgs %
92.1%
Holding
24
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$99M
2
CSLT
CASTLIGHT HEALTH, INC.
CSLT
+$1.25M
3
LUNG icon
Pulmonx
LUNG
+$181K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$294M
$131M 24.77%
3,379,064
– –
LEGN icon
2
Legend Biotech
LEGN
$3.93B
$59.2M 11.19%
1,629,173
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$9.8B
$58M 10.96%
2,449,183
– –
ARWR icon
4
Arrowhead Research
ARWR
$12.1B
$58M 10.96%
1,260,869
-2,000,000
-61% -$99M
MGTX icon
5
MeiraGTx Holdings
MGTX
$1.17B
$40.1M 7.59%
2,898,550
– –
HLTH
6
DELISTED
Cue Health Inc. Common Stock
HLTH
$35.8M 6.77%
5,548,864
– –
PRCT icon
7
Procept Biorobotics
PRCT
$1.26B
$35.6M 6.74%
1,018,478
– –
FUSN
8
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$28.5M 5.39%
3,670,516
– –
CVRX icon
9
CVRx
CVRX
$78.3M
$20.9M 3.96%
3,495,575
– –
XNCR icon
10
Xencor
XNCR
$1.71B
$20M 3.77%
748,062
– –
ACET icon
11
Adicet Bio
ACET
$77.3M
$14.6M 2.75%
45,559
– –
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.97M 1.51%
1,000,000
– –
VOR icon
13
Vor Biopharma
VOR
$1.38B
$6.49M 1.23%
53,733
– –
PHGE icon
14
BiomX
PHGE
$1.67M
$4.12M 0.78%
11,228
– –
SLGC
15
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$2.25M 0.43%
281,052
– –
PHAS
16
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.12M 0.4%
1,607,044
– –
NNOX icon
17
Nano X Imaging
NNOX
$73.2M
$2.09M 0.39%
192,429
– –
ALDX icon
18
Aldeyra Therapeutics
ALDX
$86.9M
$1.75M 0.33%
394,834
– –
TCON
19
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$221K 0.04%
4,200
– –
SENS icon
20
Senseonics Holdings Inc
SENS
$409M
$108K 0.02%
2,731
– –
CALC icon
21
CalciMedica
CALC
$20.2M
$61K 0.01%
3,539
– –
GYRE icon
22
Gyre Therapeutics
GYRE
$693M
$44K 0.01%
8,927
– –
LUNG icon
23
Pulmonx
LUNG
$92.8M
– –
-5,639
Closed -$181K
CSLT
24
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-811,295
Closed -$1.25M

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q1 2022 Portfolio in Review

As of Q1 2022, Johnson & Johnson held 24 positions worth $529M, down 40% from $878M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Johnson & Johnson withdrew a net $100M in Q1 2022, closing 2 positions and reducing 1 holding. Its most notable exit was CASTLIGHT HEALTH, INC., an estimated $1.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

  • Johnson & Johnson's biggest Q1 2022 reduction was Arrowhead Research, cutting an estimated $99M.
  • Johnson & Johnson fully exited CASTLIGHT HEALTH, INC. in Q1 2022, selling an estimated $1.25M.
  • Johnson & Johnson's ten largest holdings make up 92% of its $529M portfolio in Q1 2022.
  • Johnson & Johnson opened 0 new positions and closed 2 in Q1 2022.
  • Johnson & Johnson's portfolio value fell 40% quarter-over-quarter to $529M.

Based on Johnson & Johnson's 13F filing for Q1 2022, filed 9 May 2022.